BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
search help
Documents 1-11 out of 11 found
  Current Search:  halfan: 24, halofantrine: 31, hydrochloride: 3359  
100%
TEXT
http://www.fda.gov/cder/orange/appendix_a.txt
ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL...

Matching: halfan halofantrine hydrochloride Find similar documents More document info
100%
HTML
FDA Drug Approvals List
- 2002 January February March April May June July August - 2001 January February March April May June July August September October November December - 2000 January February March April May June July August September October November December - 1999 January February March April May June July August September October November December - 1998 January February March April May June July...
Matching: halfan halofantrine hydrochloride Find similar documents More document info
100%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf
1 HL: L4 PRESCRIBING INFORMATION HALFAN a a brand of halofantrine hydrochloride Tablets WARNING: HALFAN HAS BEEN SHOWN TO PROLONG QTc INTERVAL AT THE RECOMMENDED THERAPEUTIC DOSE
DESCRIPTION Halfan (halofantrine hydrochloride) is an antimalarial drug available as tablets containing 250 mg of halofantrine hydrochloride (equivalent to 233 mg of the free base) for...

Matching: halfan halofantrine hydrochloride Find similar documents More document info

100%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 4


Matching: halfan halofantrine hydrochloride Find similar documents More document info

100%
HTML
Drug Approvals for August 1997
Drug Approvals for August 1997 Definitions and Notes August 1997 Original New Drug Applications Original Application #: 020808 Approval Date: 29-AUG-97 Trade Name: VISIPAQUE Chemical Type: 3 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: NYCOMED INC Active Ingredient(s): IODIXANOL OTC/RX Status: RX Indication(s): Intra-arterial - for visceral intra-arterial digital...
Matching: halfan halofantrine hydrochloride Find similar documents More document info
78%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 8


Matching: halfan halofantrine Find similar documents More document info

78%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 6


Matching: halfan halofantrine Find similar documents More document info

78%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 5


Matching: halfan halofantrine Find similar documents More document info

78%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 3


Matching: halfan halofantrine Find similar documents More document info

78%
PDF
http://www.fda.gov/cder/foi/label/2002/20250s7s8lbl.pdf page 1


Matching: halfan halofantrine Find similar documents More document info

78%
PDF
Medicines, Ethics and Practice page 3


Matching: halfan halofantrine Find similar documents More document info

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.